Darryl R. Davis* Pages 1 - 12 ( 12 )
Heart failure is a significant source of morbidity and mortality around the world. Recently, cell therapy has garnered much attention as a means of improving cardiac function after injury. Despite years of study, a growing list of failed efficacy trials has led many to question the translatability of preclinical work. In this review, we critically evaluate the evidence supporting the need for transplanted cells to engraft and persist in the injured heart (the cell engraftment hypothesis). We explore how the complex interplay between cell retention, persistence and paracrine potency explain many of the recent cell treatment outcomes. Through this discussion, we outline a framework to understand how future approaches will optimize and personalize the methods, payloads and timing of cardiac cell delivery for the millions of patients worldwide suffering from heart failure.
stem cell, heart failure, engraftment, cytokine, exosome, differentiation
Division of Cardiology, University of Ottawa Heart Institute, Ottawa, K1Y 4W7